Royalty Report: Drugs, Cancer, Disease – Collection: 52353

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Pain
  • Technical Know How
  • Pharmaceuticals
  • Diagnostic
  • Therapeutic
  • Electrical & Electronics
  • Delivery
  • Tissue
  • Transportation
  • Automotive
  • Engines
  • Computers & Office Equipment
  • Consumer Electronics
  • Gastrointestinal
  • Biotechnology
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 52353

License Grant
Pursuant to a Worldwide License Agreement,  and that certain Iloperidone Sublicense Agreement, this agreement addresses current compensation for the License Agreement.  The original agreement grants an exclusive license in the field under the patents and know-how to develop, have developed, make, have made, use, import, sell, offer for sale and have sold compound and product in the territory.
License Property
Licensor is the owner of all right, title and interest in certain patents and patent applications, and know-how relating to a compound known as Iloperidone, whose more specific chemical name is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Patents include
US –  07/354,411  abandoned;  US –  07/456,790  abandoned;  EP –  90/09208.0,  granted    0 402 644 B1;  Austria –  55770/90,  issued   640,653;  Canada –  2,017,193-6;  China –  90103721.4;  Czech Republic   –   2425-90;  Finland –  902449;  Hungary – 3090/90;  Israel  –  94425;  Japan – 127090/90,  issued  1931594;  Korea  –  90/7102;  Mexico –  20787;  Norway  –  P902214, 177301;  Philippines  –  40530;  Poland –  P-285247,  163965;  Russia –  4743876/04;  US – 07/619,825  continuation   abandoned;  US – 07/944,705  continuation   abandoned;  US –  07/788,269  abandoned;  US –  07/969,383  issued  5,364,866;  PCT –  92/09276   WO/93/09102;  EP –  92/924151.1;  EP (PT)  –  92/118992.5; Austria –  30570/92;  Belarus  – 1715;  Canada –  2,121,253; Czech Republic  – PV 1102-94; Finland –  942052; Georgia –  001977; Hungary –  P9401316; Israel  – 103622; Japan –  5-508591; Korea  –  94-701524; Kazakhstan – 941593.1; Mexico –  926370; Norway – 941647; New Zealand  –  245006; Philippines  –  45259; Poland – P-303452; Romania – 9400761;  Russia – 94028105.04; Slovak Republic  –   PV 0456-94; Taiwan – 81108831; Uzbekistan  –  9500706.1; US  – 08/144,265   abandoned; US – 08/309,395  pending; US –  08/329,000  allowed; US – 08/468,611  pending; PCT – 94/12054    WO95/11680; Canada –  94/12054; China –  94194302.X; Czech Republic   –   PV 1238-96; Hungary –  P/P 00576     06/29/95,  211,853    11/05/95     06/29/2015; Indonesia – 951058; Ireland – 94/12054; Israel – 111,498; Japan – 512724/1995; Korea – 96-702162; Mexico – 94 8405;Norway –  p961686; New Zealand – 275941; Poland  –  P314135; Romania – 96-00888; Russia  –  96110214; Taiwan  –  83110396; South Africa  –  95/2653

Field of Use
The field is the treatment in humans of psychiatric disorders, psychotic disorders and analgesia.

IPSCIO Record ID: 7516

License Grant
The Licensor hereby agrees, unconditionally and irrevocably, that the Licensee shall have the exclusive and unrestricted right worldwide, to exercise, use and commercialize and allow third parties to exercise, use and commercialize the Invention during the Agreed Term.

Invention shall thereafter mean the inventions covered by any claim(s) of a Patent issued or validated in the USA, the United Kingdom, France or Germany and not subsequently invalidated.

License Property
Patent and Patent Applications

Israel Patent Application 123998 (which is priority document for all patents/patent applications listed below)

PCT/IL99/00173 (all patents/patent applications listed below via this application).

Europe   European Patent Application EP 1071702 B1 covering   Austria Belgium Cyprus Denmark Finland France Germany Greece

Ireland

Italy

Latvia

Lithuania

Luxembourg

Monaco

Netherlands

Portugal

Romania

Slovenia

Spain

Sweden

Switzerland (+Liechtenstein)

United Kingdom

Other European Applications

Czech Republic
PV 2000-3625

Hungary
P 01 01653

Norway
20004998

Poland
P 343 360

Ukraine
20000095546

Eurasia

Eurasian Application No. 200000888 covering

Armenia
Azerbaijan
Belarus
Kazakhstan
Kirgizstan
Moldova
Russia
Tajikistan
Turkmenistan

Americas

Brazil
9909908-0

Canada
2,325,933

Mexico
009863

United States  6,395,722(granted), 6,384,024(granted), 10/078,671

Others

Australia
30515/99 (granted)

China
99804903.4

Indonesia
W2000 1998

Japan
2000-543488

New Zealand
507309

South Korea
10-2000-7010903

Turkey
84564

IPSCIO Record ID: 257617

License Grant
This amendment addresses new parent for Licensor, territories and royalties.

With the original agreement, Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Irinotecan is used as a chemotherapy drug.
MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 recently achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer.

IPSCIO Record ID: 152770

License Grant
Licensor grants to the Japanese Licensee a perpetual, exclusive license, with the right to grant sublicenses, under Licensors Patents and know-how to make, have made, use, sell and have sold product and finished product within the field and territories.
License Property
Patents and know-how are relating to products directed against Macrophage Migration Inhibitory Factor (MIF), and the use of such products for the potential palliation, evaluation, diagnosis and treatment and/or prophylaxis of human disease states which are caused or exacerbated by MIF.  The products are those in which composition of matter contains antibodies against MIF.

Macrophage migration inhibitory factor (MIF or MMIF), also known as glycosylation-inhibiting factor (GIF), L-dopachrome isomerase, or phenylpyruvate tautomerase is a protein that in humans is encoded by the MIF gene.

Field of Use
The field shall mean use of the products for in vivo therapy of human disease and in vivo diagnosis and in vitro diagnosis and evaluation of human tissue or fluid.

IPSCIO Record ID: 266853

License Grant
Licensor grants the German Licensee a non-transferable, exclusive license, with the right to sublicense, under the Licensed Product Patents to develop, commercialize, market, sell and distribute, but not manufacture, the Licensed Product in the Field in the Territory.

Licensor grants a non~exclusive, non•transferable license, with the right to sublicense, to use the Licensors Mark solely within the Territory and solely in connection with the sale of the Licensed Product in the Field.

License Property
The Licensed Product shall mean any pharmaceutical form, dosage, strength, or formulation of TheraCLEC-Total purchased from Licensor.

TheraCLEC-Total shall mean commercial formulations of that product currently known as TheraCLEC-Total consisting of the enzymes, lipase, amylase and protease.

Field of Use
The Field shall mean the treatment of symptoms (e.g. malabsorption or pain) directly caused by exocrine pancreatic insufficiency.  TheraCLEC is a novel orally delivered enzyme replacement therapy that is intended to replace digestive enzymes in patients suffering from pancreatic insufficiency.

IPSCIO Record ID: 257476

License Grant
For Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Irinotecan is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Irinotecan is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.

Field of Use
Irinotecan is used as a chemotherapy drug.

IPSCIO Record ID: 301547

License Grant
Licensor granted Polish Sublicensee an exclusive sublicense, even as to Licensor, for the patent rights Licensor licensed pursuant to the HPI License within the following countries Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia. The sublicense agreement provides that Sublicensee must use commercially reasonable development efforts to attempt to develop and commercialize licensed products in the above mentioned territories.

Under the HPI License Licensor obtained the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer anywhere in the world

License Property
Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known and as a class are effective against more types of cancer than any other class of chemotherapeutic agents.
Field of Use
The chemical compound is commonly known as Berubicin and used in the treatment of glioblastoma.  Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.

IPSCIO Record ID: 257586

License Grant
This amendment reflects the new parent of the Licensor, re-assignment of a sublicense, territories and royalties.

Licensor of Bermuda and its Parent, the Licensee, desire to amend the Agreement to transfer back to Licensor the right to develop and commercialize the Licensed Product in certain countries in Asia.   The original agreement was exclusive.

License Property
The Licensor has rights relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Liposomal irinotecan is used in chemotherapy.

IPSCIO Record ID: 1298

License Grant
Licensor hereby grants to Japanese Licensee, and to Licensee's present and future subsidiaries, affiliates, and other companies in which Licensee owns at least 50% of the stock or assets, the rights and license.
License Property
Licensor is the owner of patents on blade fuses, and of registered trademark(s) (Mini-Fuse, Min, ATO, etc.)on a blade fuse configuration, and has claimed ownership of certain technology (know-how) and of certain trade dress on certain elements of a blade fuse configuration.

AUTOFUSE(R) or ATO(R), a standard blade type fuse, is used in automobiles produced worldwide and designed to provide superior circuit protection in a small, heat resistant package for low ampere applications.

MINI(R) Fuse, smaller than its predecessor AUTOFUSE(R), is offered in a range from two amps to 30 amps and is designed to permit more fuses in the same amount of space than prior products.

Field of Use
The Company currently licenses its ATO(R) and MINI(R) automotive fuse technology to a Japanese manufacturer that produces and distributes the Company's patented automotive fuses to Pacific Rim operations of Pacific Rim-based automotive manufacturers.

IPSCIO Record ID: 27938

License Grant
The Licensor grants exclusively to the Canadian Licensee, the rights to utilize the technology so described in the following patents Light Source Device of Side Emitting Back Light Module; Light Source Device of Backlight Module; Light Guide Plate; TV Reception modular Device; Connecting device between Back-lighting bulb and wire; Side-Emitting light source for Back -lighting module.
License Property
Patents
Light Source Device of Side Emitting Back Light Module
M305912
2/1/2007
Rep. of China; Taiwan, China, Japan, Korea
Yeh-He Lo

Light Source Device of Backlight
Module
M305911
2/1/2007
Rep. of China; Taiwan, China, Japan, Korea
Yeh-He Lo

Light Guide Plate
M300824
11/11/2006
Rep. of China; Taiwan, China
Yeh-He Lo

TV Reception modular Device
c
9/21/2006
Rep. of China; Taiwan, Spain, China, France, Germany
Yi-Hsiang

Connecting device between Back
-lighting bulb and wire
M298070
9/21/2005
Rep. of China; Taiwan, China, Japan, Korea
Yi-Hsiang

Side-Emitting light source for Back -lighting module
#95216477
9/15/2006
Rep. of China; Taiwan, China, Japan, Korea
Yi-Hsiang
Yi-Hs

Field of Use
The field of use relates to the Back/Light Module for LCD screens industry.

IPSCIO Record ID: 166962

License Grant
Licensor grants an exclusive license in the field under the patents and know-how to develop, have developed, make, have made, use, import, sell, offer for sale and have sold Compound and Product in the Territory.

Licensor grants a non-exclusive, worldwide license to make or use any analytical reference standards, intermediate or metabolite of Compound or Product not listed hereto which may be claimed.

License Property
Licensor is the owner of all right, title and interest in certain patents and patent applications and know-how relating to the chemical compound known as Iloperidone.

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.

Field of Use
The field shall mean the treatment in humans of psychiatric disorders, psychotic disorders and analgesia.

IPSCIO Record ID: 259855

License Grant
Licensor grants the Sublicensee, of Poland, an exclusive sublicense even as to Licensor under the Sublicensed Subject Matter to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell Sublicensed Products within the Sublicensed Territories for use within the Sublicensed Field.

Licensor has obtained licenses to research, develop, make, have made, use, offer to sell, sell, export and/or import and commercialize Licensed Products within the Licensed Territory for use within the Licensed Field under Patent Rights.

License Property
The grant is for certain intellectual property rights, including rights to Annamycin, Licensors WP1122 portfolio, and WP1066 portfolio.
Field of Use
The Sublicensed Field means the field of pharmaceutical drug products for the treatment of any illness, disease, or symptom in humans.

Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.

IPSCIO Record ID: 257477

License Grant
The Licensor of China assigns and transfers to the SubLicensee of Bermuda all of Licensors rights and obligations under the License Agreement.

Licensor grants
—  an exclusive right and license under the Licensors Licensed Technology and rights to the Joint Technology, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export the Licensed Compound and the Licensed Product in the Field outside the Licensor Territory; provided that Licensor reserves the right to conduct Development activities outside the Licensor Territory solely to support the Development and Commercialization of Licensed Compound and Licensed Products inside the Licensor Territory, and manufacture Licensed Compound and Licensed Products outside the Licensor Territory solely for use and distribution within the Licensor Territory; and,

— a non-exclusive right and license in the Field in the Licensor Territory under the Licensor Licensed Technology and rights to the Joint Technology, to the extent necessary for SubLicensee to perform its obligations under the Development Plan, and to Develop and manufacture the Licensed Compound and the Licensed Product in the Licensor Territory solely in support of Development and Commercialization of the Licensed Compound and the Licensed Product outside the Licensor Territory.

Previously, the development and commercialization rights to MM-398 in Europe and Asia had been licensed to Licensor. Sublicensee held the rights to the product in North America and all other territories around the world. Through this agreement, the worldwide rights to MM-398 have been reunited, with SubLicensee now having the right to develop and commercialize MM-398 in all territories of the world with the exception of Taiwan, where Licensor will retain its rights to develop and commercialize MM398.

License Property
MM-398 is a highly stable nanoliposomal formulation of irinotecan.  MM-398, or irinotecan, is used with chemotherapy treatments.

The property of the original agreement which is being reassigned with this agreement is
Intellectual property relating to liposomal irinotecan;  Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 46,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof;  and,  patents for Liposomes Useful for Drug Delivery.

Field of Use
Field means all human and veterinary fields of use, including therapeutic, prophylactic, palliative and diagnostic uses in all possible indications.   MM-398, or irinotecan, is used with chemotherapy treatments.

IPSCIO Record ID: 271161

License Grant
For the Research and Development License, Licensor grants to the German Licensee during the R&D Term a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology and under Licensors rights in the Joint Patents, Joint Research Technology and Joint Know-How, solely to conduct the Research, to characterize, optimize, research and develop the Development Compounds into Licensed Products in the Field and to make, have made and use Collaboration Compounds in the Field solely for research and development purposes in accordance with the Research and Development Plan and each Semi-Annual R&D Plan.

For the Commercialization License, Licensor grants to Licensee and its Affiliates a co-exclusive, with Licensor, right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to make, have made, import and use Licensed Products for use in the Field; and an exclusive, including with regard to Licensor right and license in the Territory under the Licensor Patents and the Licensor Know-How and Research Technology, and under Licensors rights in the Joint Know-How, Joint Research Technology and Joint Patents, to sell and offer for sale Licensed Products for use in the Field.

License Property
Licensor possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.

Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound.  Development Compound means any Collaboration Compound that has been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.

The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.

Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.

Field of Use
Field means the treatment or prevention in humans of one or more Indications.   Indication means ulcerative colitis; and other gastrointestinal and liver diseases.

Ulcerative colitis is a long-term condition that results in inflammation and ulcers of the colon and rectum.

IPSCIO Record ID: 257485

License Grant
The Licensor of Switzerland and the Licensee now desire to modify their arrangements under the Original Agreement to provide, among other things, for the relinquishment of the sublicenses and licenses granted by Licensor to Licensee under the Original Agreement in the U .S./Canadian Territory, for the grant by Licensee to Licensor of exclusive license rights with respect to certain Licensee Know-How and Licensee Trademarks and for the assignment by Licensee to Licensor of the Existing Applications and Approvals and the Licensee Domain Names.

The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents licensed to Licensor or its Affiliates and an Exclusive license in the Field under the Patents, except for the Biomarker Patent, owned by Licensor or its Affiliates,  an Exclusive sublicense and license, as applicable, in the Field under the Know-How and a non-exclusive license in the Field under the Patent owned by Licensor covering the biomarker, in each case, to research, develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the ROW Territory,

Licensor grants a non-exclusive, ROW Territory sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product, not listed, which may be claimed in Patents in the ROW Territory limited solely to making or using the Compound or Product.

License Property
Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is I-[ 4-[3 -[ 4-( 6-fluoro-1,2-benzisoxazol-3-y 1 )-1-piperidiny l] propoxy]-3-methoxyphenyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Product shall mean any bulk or finished pharmaceutical composition containing the Compound as a pharmaceutically active ingredient for use in the Field.

Depot Formulation shall mean any extended-release, injectable formulation of the Compound.

The parties acknowledge and agree that Products sold within the United States will be sold only under the  trademark FANAPTâ„¢.

Field of Use
Field shall mean application to all conditions, disorders and diseases in humans.  The licensed patents field of use is as antipsychotic drugs.

IPSCIO Record ID: 7182

License Grant
The SubLicensor is the exclusive licensee of the Patent Rights  under the Exclusive License Agreement and is willing to grant to a royalty-bearing Sublicense.

The Sublicensor hereby grants to the French SubLicensee, a co-exclusive, royalty-bearing SubLicense to the Patents, in the territory in the Field during the Term.

License Property
The term diagnosis includes Research Use Only, in Vitro Diagnostic and Analyte specific reagent fields.

Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, as well as all continuations, divisions, reissues, re-examinations, renewals, or extensions of such patents subject to the rights granted by Original Licensor to the SubLicensor pursuant to the Exclusive License Agreement, as limited by this Agreement.

Field of Use
Field shall mean diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow or blood cells. The Field specifically excludes IVD Laboratory Services testing and use of NPM1 as a drug target.

IPSCIO Record ID: 257486

License Grant
The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents, to the extent, but only to the extent, that such patents or patent applications claim the Compound or Product or the manufacture, formulation, or use thereof, and Know-How to develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the Territory, subject to the terms and conditions of this Sublicense Agreement.

Licensor grants a non-exclusive, worldwide sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product which may be claimed in Patents limited solely to making or using the Compound or Product.

Licensee represents and warrants that during the term of this Sub license Agreement, neither it, an Affiliate or a Sublicensee shall license, develop, have developed, manufacture, have manufactured, sell or have sold any of the following compounds or products classified as an atypical antipsychotic i.e. Olanzapine, Sertindole, Seroquel, Ziprasadone, Risperidone.

License Property
Licensor has rights to certain patents and patent applications, and know-how relating to a compound known as Iloperidone.

Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is 1 -[ 4-(3-[ 4-(6-fluoro-l ,2-benzisoxazol-3-y 1)-1-piperidinyl]propoxy ]-3-methoxyphcnyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Field of Use
The Field shall mean application to all conditions, disorders and diseases in humans.  The licensed property use is for therapeutic treatment of schizophrenic patients.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.